



## Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021

August 6, 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Aug. 6, 2021-- [Forma Therapeutics Holdings, Inc.](#) (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release second quarter 2021 financial results Friday, Aug. 13, 2021. Forma management will host an investment community conference call at 8 a.m. Eastern Time, on Aug. 13, 2021, to discuss these financial results and provide a business update.

Investors may participate by dialing +1 (833) 301-1146 in the U.S. or Canada, or +1 (914) 987-7386 internationally, and by referring to Conference ID 9155938. A live webcast of the conference call will be available in the "News & Investors" section of Forma's website at [www.formatherapeutics.com](http://www.formatherapeutics.com).

### About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit [www.FormaTherapeutics.com](http://www.FormaTherapeutics.com) or follow us on Twitter @FORMAInc and LinkedIn.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210806005026/en/): <https://www.businesswire.com/news/home/20210806005026/en/>

### Investor Contact:

Mario Corso, +1 781-366-5726

Forma Therapeutics, Inc.

[mcorso@formatherapeutics.com](mailto:mcorso@formatherapeutics.com)

Source: Forma Therapeutics Holdings, Inc.